Hikma Pharmaceuticals Regulatory News (HIK)

Hikma Pharmaceuticals PLC

Interim & Special Dividend for 2013

LONDON, 4 October 2013 - Hikma Pharmaceuticals PLC ("the Company") advises that, as previously announced with the interim results, the Company is paying a total dividend of 10 cents per share, comprising the interim dividend of 7.0 cents and the special dividend of 3 cents, on 7 October 2013 to shareholders on the register on 6 September 2013.

Shareholders who have elected to receive their dividend in Pounds Sterling will receive 6.26 pence per Ordinary Share (exchange rate US$1.5974 to GBP£1).

Shareholders who have elected to receive their dividend in Jordanian Dinar will receive 7.08 qirsh (piastres) per Ordinary Share (exchange rate US$0.708 to JOD1).

- ENDS -

Enquiries:

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2012, Hikma achieved revenues of $1,108.7 million and profit attributable to shareholders of $100.3 million.